Navigation Links
Additional Data From Satraplatin SPARC Phase 3 Trial Presented at,European Association of Urology Congress

= distressing pain, 4 = horrible pain and 5 = excruciating pain. The criteria for pain response are a greater than or equal to 2 point reduction in the patients' weekly PPI score from baseline and maintenance of the two point reduction for at least five consecutive weeks in the setting of a stable or decreasing weekly analgesic score compared to baseline. Patients were evaluable for pain response if their baseline PPI score was greater than or equal to one and had completed four consecutive weekly assessments of PPI and analgesic scores during the study treatment.

Data from the SPARC trial also showed that the prostate specific antigen (PSA) response rate for patients treated with satraplatin was significantly improved compared to the PSA response rate for those patients in the placebo arm. PSA response rates were 25.4 percent for the satraplatin plus prednisone arm compared with 12.4 percent for the placebo arm (p<0.001).

PSA response was analyzed using the widely adopted Bubley criteria of a decrease of PSA level by greater than or equal to 50 percent from baseline, with confirmation at least four weeks later.

"We believe the PSA response rate provides important information especially in this challenging second-line context," said Andrew Allen, Pharmion's chief medical officer and executive vice president. "To see this level of response for both pain and PSA is very encouraging and provides important additional insight on the clinical profile of satraplatin in patients with advanced prostate cancer."

Marcel Rozencweig, M.D., chief medical officer and senior vice president, drug development of GPC Biotech said: "Patients with hormone-refractory prostate cancer frequently suffer from terrible pain associated with bone metastases. The satraplatin data presented today continue to build on the progression-free survival data already presented from the SPARC trial."

The pain and PSA response analyses, in addition to the previously pres
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
2. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
3. Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR
4. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
5. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
6. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
7. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
8. Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
11. Additional Efficacy Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at Annual Meeting of American Urological Association
Post Your Comments:
(Date:1/15/2014)... Most osteoporosis patients want a choice in the medication ... by Mission Pharmacal Company. The survey, conducted by ... community, revealed that 74 percent of osteoporosis patients surveyed ... other than a pill or a tablet. ...
(Date:1/15/2014)... AARP Foundation today announced it has established a ... severe cold weather that has gripped much of the nation. ... need; so to support these emergency relief efforts AARP and ... could mean up to $500,000 in aid. The matching program ...
(Date:1/15/2014)... THOUSAND OAKS, Calif. , Jan. 15, 2014 ... and Amgen (NASDAQ: AMGN ) announced ... to jointly discover and validate new therapeutic targets ... (IBD), a chronic disorder that affects millions worldwide. ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4
... 2011 Mylan Inc. (Nasdaq: MYL ) ... announced refinancing of its existing secured credit facility. The ... upsized from the originally planned $2.25 billion and comprises ... billion Term Loan A facility. The proceeds were used ...
... CLEVELAND and GAITHERSBURG, Md., Nov. 14, 2011 University ... School of Medicine and Lentigen Corporation announced today the ... LG631 gene therapy for the protection of hematopoietic stem ... with Temodar.   Approximately 17,000 Americans are ...
Cached Medicine Technology:Mylan Successfully Upsizes and Completes Refinancing of Credit Facility 2Lentigen and UH Case Medical Center Initiate Phase I Trial Using Gene Therapy and Bone Marrow Stem Cells in the Treatment of Brain Cancer 2Lentigen and UH Case Medical Center Initiate Phase I Trial Using Gene Therapy and Bone Marrow Stem Cells in the Treatment of Brain Cancer 3Lentigen and UH Case Medical Center Initiate Phase I Trial Using Gene Therapy and Bone Marrow Stem Cells in the Treatment of Brain Cancer 4
(Date:7/13/2014)... Wa (PRWEB) July 13, 2014 According ... by Vkool.com, this is a comprehensive guide that features ... deal with KP (keratosis pilaris). This guide ... 1: What Is Keratosis Pilaris? ,     Chapter 2: ... I Know If I Have KP? ,     Chapter ...
(Date:7/12/2014)... Fadhits.com, a well-known wedding dress manufacturer and retailer, has added ... to its product line. In addition, the company has launched ... bring more benefits for its loyal fans. All its ... to 72% off. , As a leader in the garment ... is a good place for ladies who want to purchase ...
(Date:7/12/2014)... 12, 2014 The Passenger Information System ... 2013 to $20,341.36 million by 2019, at an expected ... 2019. , The public transport infrastructure in North America ... available in almost every corner of the region. The ... of public transport service providers are driving the North ...
(Date:7/12/2014)... 12, 2014 The report, "Phthalic Anhydride ... Market by Application & Geography – Trends & Forecast ... analysis and forecasting of market volume and value. The ... derivatives separately. The market of phthalic anhydride is projected ... to $8,415.89 million by 2018, with a CAGR of ...
(Date:7/12/2014)... Dallas, TX (PRWEB) July 12, 2014 ... training market research report, ‘cognitive assessment and ... able to monitor, assess, train, or enhance ... several uses such as in dementia screening, ... concussion management, classroom learning, self assessment, brain ...
Breaking Medicine News(10 mins):Health News:Living With KP Book Review Exposes Jennifer Richards' Keratosis Pilaris Guide – Vkool.com 2Health News:Living With KP Book Review Exposes Jennifer Richards' Keratosis Pilaris Guide – Vkool.com 3Health News:New Collection of Long Graduation Dresses Revealed by Fadhits.com 2Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 4Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 2Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 3Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 4Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 2Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 3Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 4Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 5
... prompt consumers, food industry to consider ... benefits of natural sea salt, ... a dinner plate - yet that,s exactly what millions,of Americans unwittingly ... table salt, says Mark Zoske, co-founder of SaltWorks, Inc.,( http://www.seasalt.com ), ...
... -- China,Shenghuo Pharmaceutical Holdings, Inc. (Amex: KUN ... in the research, development, manufacture,and marketing of pharmaceutical, ... of China ("PRC"), today announced it will,conduct a ... April 2, 2008, to,discuss the Company,s financial results ...
... ... Enroll in Wellness Programs and Believe, that Yoga, Tai Chi and Other ... ... grow in,popularity, employees overwhelmingly see value in these healthy activities,but don,t stay committed to ...
... - Reduce pollution, save money., CHICAGO, March 31 ... "green" record by launching an innovative Shared,Bike Program on ... The Museum is a trendsetter for employee bicycle ... showers and bike parking,including a large, secure, indoor bike-parking ...
... a leading provider of laser vision correction services ... 76th LasikPlus(R) vision,center in Woodbridge, New Jersey. This ... year, and the second vision center,located in Northern ... Paramus in April 2006., Similar to other ...
... Inc. (Nasdaq: STRM ) today announced the financial ... 31, 2008., Revenues in the fourth quarter of ... with $3.8 million in the fourth quarter of fiscal,year ... $781 thousand, a,153% increase, compared with an Operating Profit ...
Cached Medicine News:Health News:SaltWorks, Inc. Advises Table Salt Alternatives 2Health News:China Shenghuo Pharmaceutical Holdings, Inc. Schedules Conference Call to Discuss FY 2007 Results 2Health News:China Shenghuo Pharmaceutical Holdings, Inc. Schedules Conference Call to Discuss FY 2007 Results 3Health News:Guardian Survey: Despite Perceived Effectiveness, Most Employees Who Participate in Wellness Programs Do Not Stay Committed 2Health News:Guardian Survey: Despite Perceived Effectiveness, Most Employees Who Participate in Wellness Programs Do Not Stay Committed 3Health News:Guardian Survey: Despite Perceived Effectiveness, Most Employees Who Participate in Wellness Programs Do Not Stay Committed 4Health News:Field Museum Launches Shared Bike Program for Employees 2Health News:LCA-Vision Announces the Opening of its 76th LasikPlus(R) Vision Center in Woodbridge, New Jersey 2Health News:Streamline Health Solutions, Inc. Reports Fourth Quarter and Fiscal Year 2007 Results 2Health News:Streamline Health Solutions, Inc. Reports Fourth Quarter and Fiscal Year 2007 Results 3Health News:Streamline Health Solutions, Inc. Reports Fourth Quarter and Fiscal Year 2007 Results 4Health News:Streamline Health Solutions, Inc. Reports Fourth Quarter and Fiscal Year 2007 Results 5Health News:Streamline Health Solutions, Inc. Reports Fourth Quarter and Fiscal Year 2007 Results 6Health News:Streamline Health Solutions, Inc. Reports Fourth Quarter and Fiscal Year 2007 Results 7Health News:Streamline Health Solutions, Inc. Reports Fourth Quarter and Fiscal Year 2007 Results 8Health News:Streamline Health Solutions, Inc. Reports Fourth Quarter and Fiscal Year 2007 Results 9Health News:Streamline Health Solutions, Inc. Reports Fourth Quarter and Fiscal Year 2007 Results 10Health News:Streamline Health Solutions, Inc. Reports Fourth Quarter and Fiscal Year 2007 Results 11Health News:Streamline Health Solutions, Inc. Reports Fourth Quarter and Fiscal Year 2007 Results 12Health News:Streamline Health Solutions, Inc. Reports Fourth Quarter and Fiscal Year 2007 Results 13
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Infusion Cannula, 6.0mm....
Subretinal Injection Cannula, Curved; 20g (0.90) x 1" (25mm); Tip Extension: 3mm, 32g (0.23); Angled at 35°....
Injection Cannula, Angled; 20g (0.90) x 1" (25mm); Tip Extension: 5mm, 30g (0.30); Angled at 45°, 2.5mm from Tip....
Medicine Products: